Table 1 The comparison of 24 months survival and galectin-3 expression in selected groups of patients.
From: Galectin-3 and cyclin D1 expression in non-small cell lung cancer
Survival | Positive galectin-3 expression n (%) | Negative galectin-3 expression n (%) | Chi2 Yatesa | p | Cox Mantel |
|---|---|---|---|---|---|
All examinated patients with NSCLC | |||||
< 24 months | 8 (44.44%) | 12 (41.38%) | 0.01 | 0.922 | 0.841 |
≥ 24 months | 10 (55.56%) | 17 (58.62%) | |||
The patients with squamous cell carcinoma | |||||
< 24 months | 5 (45.45%) | 5 (38.46%) | 0.00 | 0.944 | 0.612 |
≥ 24 months | 6 (54.55%) | 8 (61.54%) | |||
The patients with adenocarcinoma | |||||
< 24 months | 2 (50%) | 6 (54.55%) | 0.18 | 0.667 | 0.695 |
≥ 24 months | 2 (50%) | 5 (45.45%) | |||
Stage I | |||||
< 24 months | 1 (33.33%) | 2 (14.29%) | 0.00 | 0.960 | 0.434 |
≥ 24 months | 2 (66.66%) | 12 (85.71%) | |||
Stage II | |||||
< 24 months | 2 (40%) | 3 (100%) | 0.89 | 0.345 | 0252 |
≥ 24 months | 3 (60%) | 0 (0%) | |||
Stage III | |||||
< 24 months | 2 (28.57%) | 5 (55.56%) | 0.33 | 0.567 | 0.275 |
≥ 24 months | 5 (71.43%) | 4 (44.44%) | |||
Stage IV | |||||
< 24 months | 3 (100%) | 2 (66.67%) | 0.00 | 1.00 | 0.341 |
≥ 24 months | 0 (0%) | 1 (33.33%) | |||